Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction

M. Balik, A. Novotny, D. Suk, V. Matousek, M. Maly, T. Brozek, G. Tavazzi,

. 2020 ; 34 (5) : 685-688. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027762

PURPOSE: Left ventricular outflow tract obstruction (LVOTO) is a relatively uncommon but severe condition that may lead to hemodynamic impairment. It can be elicited by morphological (left ventricular hypertrophy, sigmoid septum, prominent papillary muscle, prolonged anterior mitral valve leaflet) and functional (hypovolemia, low afterload, hypercontractility, catecholamines) factors. We sought to determine the incidence of the most severe form of LVOTO in septic shock patients and describe the therapeutic effects of vasopressin. METHODS: Over a period of 29 months, 527 patients in septic shock were screened for LVOTO. All were mechanically ventilated and treated according to sepsis bundles, including pre-load optimization and norepinephrine infusion. Vasopressin was added in addition to norepinephrine to reduce the adrenergic burden and decrease LVOTO. RESULTS: Ten patients were diagnosed with the most severe form of LVOTO, including systolic anterior mitral valve motion (SAM) and severe mitral regurgitation (MR) with pulmonary oedema. The median norepinephrine dosage to obtain a mean arterial pressure of ≥70 mmHg was 0.58 mcg/Kg/min (IQR 0.40-0.78). All patients had a hyper-contractile left ventricle, septal hypertrophy, significant LVOTO (peak gradient 78 [56-123] mmHg) associated with SAM and severe MR with pulmonary oedema. Vasopressin (median 4 IU/h) allowed a significant reduction of norepinephrine (0.18 [0.14-0.30] mcg/kg/min; p = 0.01), LVOT gradient (35 [24-60] mmHg; p = 0.01) and MR with a significant paO2/FiO2 increase (174 [125-213] mmHg; p = 0.01). CONCLUSION: Vasopressin allowed a reduction of norepinephrine with subsequent LVOTO reduction and hemodynamic improvement of the most severe form of LVOTO, which represented 1.9% of all septic shock patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027762
003      
CZ-PrNML
005      
20210608133910.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10557-020-06998-8 $2 doi
035    __
$a (PubMed)32488425
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Balik, Martin $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia. martin.balik@vfn.cz.
245    10
$a Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction / $c M. Balik, A. Novotny, D. Suk, V. Matousek, M. Maly, T. Brozek, G. Tavazzi,
520    9_
$a PURPOSE: Left ventricular outflow tract obstruction (LVOTO) is a relatively uncommon but severe condition that may lead to hemodynamic impairment. It can be elicited by morphological (left ventricular hypertrophy, sigmoid septum, prominent papillary muscle, prolonged anterior mitral valve leaflet) and functional (hypovolemia, low afterload, hypercontractility, catecholamines) factors. We sought to determine the incidence of the most severe form of LVOTO in septic shock patients and describe the therapeutic effects of vasopressin. METHODS: Over a period of 29 months, 527 patients in septic shock were screened for LVOTO. All were mechanically ventilated and treated according to sepsis bundles, including pre-load optimization and norepinephrine infusion. Vasopressin was added in addition to norepinephrine to reduce the adrenergic burden and decrease LVOTO. RESULTS: Ten patients were diagnosed with the most severe form of LVOTO, including systolic anterior mitral valve motion (SAM) and severe mitral regurgitation (MR) with pulmonary oedema. The median norepinephrine dosage to obtain a mean arterial pressure of ≥70 mmHg was 0.58 mcg/Kg/min (IQR 0.40-0.78). All patients had a hyper-contractile left ventricle, septal hypertrophy, significant LVOTO (peak gradient 78 [56-123] mmHg) associated with SAM and severe MR with pulmonary oedema. Vasopressin (median 4 IU/h) allowed a significant reduction of norepinephrine (0.18 [0.14-0.30] mcg/kg/min; p = 0.01), LVOT gradient (35 [24-60] mmHg; p = 0.01) and MR with a significant paO2/FiO2 increase (174 [125-213] mmHg; p = 0.01). CONCLUSION: Vasopressin allowed a reduction of norepinephrine with subsequent LVOTO reduction and hemodynamic improvement of the most severe form of LVOTO, which represented 1.9% of all septic shock patients.
650    _2
$a agonisté adrenergních receptorů $x terapeutické užití $7 D000322
650    _2
$a senioři $7 D000368
650    _2
$a arginin vasopresin $x terapeutické užití $7 D001127
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a noradrenalin $x terapeutické užití $7 D009638
650    _2
$a obnova funkce $7 D020127
650    _2
$a dýchání $x účinky léků $7 D012119
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a septický šok $x diagnostické zobrazování $x farmakoterapie $x epidemiologie $x patofyziologie $7 D012772
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vazokonstriktory $x terapeutické užití $7 D014662
650    _2
$a funkce levé komory srdeční $x účinky léků $7 D016277
650    _2
$a obstrukce výtoku ze srdeční komory $x diagnostické zobrazování $x farmakoterapie $x epidemiologie $x patofyziologie $7 D014694
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Novotny, Adam $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
700    1_
$a Suk, Daniel $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
700    1_
$a Matoušek, Vojtěch $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia. $7 xx0260730
700    1_
$a Maly, Michal $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
700    1_
$a Brozek, Tomas $u Department of Anesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, U nemocnice 2, Prague 2, 128 08, Czechia.
700    1_
$a Tavazzi, Guido $u Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Unit of Anaesthesia and Intensive Care Fondazione Policlinico San Matteo, IRCCS, University of Pavia, Pavia, Italy.
773    0_
$w MED00001057 $t Cardiovascular drugs and therapy $x 1573-7241 $g Roč. 34, č. 5 (2020), s. 685-688
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32488425 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210608133907 $b ABA008
999    __
$a ok $b bmc $g 1608097 $s 1118942
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 5 $d 685-688 $e - $i 1573-7241 $m Cardiovascular drugs and therapy $n Cardiovasc Drugs Ther $x MED00001057
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...